Prolonged and tunable residence time using reversible covalent kinase inhibitors
J. Michael Bradshaw(Principia Biopharma (United States)), Jesse M. McFarland(Howard Hughes Medical Institute), Ville O. Paavilainen(Howard Hughes Medical Institute), Angelina Bisconte(Principia Biopharma (United States)), Danny Tam(Principia Biopharma (United States)), Vernon T. Phan(Principia Biopharma (United States)), Sergei Romanov(Nanosyn (United States)), David Finkle(Principia Biopharma (United States)), Jin Shu(Principia Biopharma (United States)), Vaishali Patel(Principia Biopharma (United States)), Tony Ton(Principia Biopharma (United States)), Xiaoyan Li(Principia Biopharma (United States)), David G. Loughhead(Principia Biopharma (United States)), Philip A. Nunn(Principia Biopharma (United States)), Dane E. Karr(Principia Biopharma (United States)), Mary E. Gerritsen(Principia Biopharma (United States)), Jens Oliver Funk(Principia Biopharma (United States)), Timothy D. Owens(Principia Biopharma (United States)), Erik Verner(Principia Biopharma (United States)), Ken A. Brameld(Principia Biopharma (United States)), Ronald J. Hill(Principia Biopharma (United States)), David Goldstein(Principia Biopharma (United States)), Jack Taunton(Howard Hughes Medical Institute)
Cited by 430Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis